Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Saved in:
| Title: | Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. |
|---|---|
| Authors: | Delimpasi S; General Hospital Evangelismos, Athens, Greece., Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain., Auner HW; The Hugh and Josseline Langmuir Centre for Myeloma Research, Imperial College London, London, UK., Gavriatopoulou M; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Dimopoulos MA; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Quach H; St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia., Pylypenko H; Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine., Hájek R; Department of Hemato-oncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic., Leleu X; Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France., Dolai TK; Nil Ratan Sircar Medical College and Hospital, Kolkata, India., Sinha DK; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India., Venner CP; Cross Cancer Institute, Edmonton, Alberta, Canada., Benjamin R; Kings College Hospital NHS Foundation Trust, London, UK., Garg MK; University Hospitals of Leicester NHS Trust, Leicester, UK., Doronin V; City Clinical Hospital #40, Moscow, Russian Federation., Levy Y; Baylor University Medical Center, Dallas, Texas, USA., Moreau P; University of Nantes, Nantes, France., Chai Y; Karyopharm Therapeutics, Newton, Massachusetts, USA., Arazy M; Karyopharm Therapeutics, Newton, Massachusetts, USA., Shah J; Karyopharm Therapeutics, Newton, Massachusetts, USA., Shacham S; Karyopharm Therapeutics, Newton, Massachusetts, USA., Kauffman MG; Karyopharm Therapeutics, Newton, Massachusetts, USA., Richardson PG; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Grosicki S; Medical University of Silesia, Katowice, Poland. |
| Source: | American journal of hematology [Am J Hematol] 2022 Mar 01; Vol. 97 (3), pp. E83-E86. Date of Electronic Publication: 2021 Dec 29. |
| Publication Type: | Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1096-8652 |
|---|---|
| DOI: | 10.1002/ajh.26434 |
